The Possible Role of Point Mutations and Activation of the CDC27 Gene in Progression of Multiple Myeloma

Abstract

Multiple myeloma (MM) is characterized by malignancy of terminally differentiated B-lymphocytes. Identification of mutations in genes and pathways in MM is crucial to elucidate the pathophysiology of this cancer. Genomic profiling of malignant myeloma cells may give unprecedented results, which may eventually lead to the development of novel drugs. MM is a complex disease with a complex interactive system that consists of dysregulation of different pathways that require precise investigation for designing more effective drugs. The recent advances in high throughput sequencing (HTS) and a better understanding of myeloma's genetic architecture provide yet another approach to uncovering the driver mutations in myeloma. In the present study, we aimed to study whether cell division cycle 27 (CDC27) has a role in MM's malignancy and performed Whole Exome Sequencing (WES) in four clinical cases. Given the importance of the CDC27 gene in cell division, various studies demonstrate in different cancers that the CDC27 gene is associated with tumor proliferation and progression. Analysis of our data in the coding region of MM cases revealed that all four cases under study carrying point mutations in multiple sites of the CDC27 gene.Interestingly, CDC27 plays a pivotal role in the anaphase-promoting complex during cell division. Therefore, we opine that CDC27 may also have a role in MM. We concluded that the effective investigation of translational genomics of CDC27 should be screened from the gene level to the functional level of the protein (bench to bedside research) and studying its possible role in MM cell progression, which might be a novel therapeutic approach.